All In MedTech

Device Trial Radar · NCT05854095

The Study for Evaluation of Acute Phase Safety and Efficacy of 'Pivot Bridge' to Short-term Treat FTR

The Study for Evaluation of Acute Phase Safety and Efficacy of 'Pivot Bridge' to Short-term Treat Functional Tricuspid Regurgitation : Multi-center, Open Label, Single Arm, Investigator Initiated Exploratory Pilot Study

Last checked: Nov 20, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Mar 13, 2023

Primary completion

Oct 17, 2023

Study completion Dec 27, 2023

Sponsor

Lead sponsor
Tau-MEDICAL Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
May 11, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

evaluation of safety and efficacy of 'Pivot Bridge' to short-term treat Functional Tricuspid regurgitation

Conditions

  • Functional Tricuspid Regurgitation

Interventions

  • Pivot BridgeDevice

    transcatheter for short-term treat Functional Tricuspid regurgitation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of Acute phase safetyTime frame: immediately after the procedure

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Bucheon Sejong Hospital

    Bucheon-si, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, Dalseo-gu, South Korea

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.